SELLAS Life Sciences Group (RXK3) Price & Analysis

1 Followers

RXK3 Stock Chart & Stats

€1.91

-€0.06(-6.19%)

At close: Jan 08 4:00 PM EST

€1.91

-€0.06(-6.19%)

Day’s Range― - ―

52-Week Range€1.20 - €7.96

Previous CloseN/A

Volume14.00K

Average Volume (3M)1.46K

Market Cap

€2.02B

Enterprise Value€999.02M

Total Cash (Recent Filing)€107.20M

Total Debt (Recent Filing)€871.00K

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Aug 06, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding186,032,580

10 Day Avg. Volume1,349

30 Day Avg. Volume1,457

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)5.80

Price to Sales (P/S)0.00

P/FCF Ratio-14.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€8.80

Price Target Upside360.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.24

Revenue Forecast (FY)€30.85M

Bulls Say, Bears Say

Bulls Say

Low Leverage And Stronger EquityVery low debt and a materially improved equity base reduce insolvency risk and provide strategic optionality. Low leverage lowers fixed financing costs, supports continued R&D spending, lengthens runway, and makes future financing less urgent or more negotiable over the medium term.

Bolstered Near-term LiquidityA reported cash position plus ~$28.7M from warrant exercises meaningfully strengthens near-term liquidity. This funding extension supports ongoing clinical programs and milestone-focused development, reducing immediate financing pressure and enabling execution of multi-month clinical plans.

Focused Oncology Immunotherapy PipelineA focused pipeline centered on cancer immunotherapies (lead candidate in hematologic malignancies and programs in HER2 cancers) aligns with durable structural demand in oncology. A clear scientific focus concentrates R&D efforts and can create durable competitive value if clinical progress continues.

Bears Say

No Meaningful Revenue; Persistent LossesThe absence of commercial revenue and recurring TTM losses mean the business cannot self-fund operations. Structurally, this forces dependence on external capital to sustain trials, limits reinvestment capacity, and keeps the company vulnerable to funding cycles until commercialization is achieved.

Persistent Negative Operating Cash FlowSustained negative operating and free cash flow reflects ongoing cash burn to support development. This pattern necessitates periodic capital raises, constrains discretionary spending, and increases execution risk if capital markets tighten, affecting continuity of multi-stage clinical programs.

Reliance On Equity-linked Financing; DilutionThe company’s use of warrant exercises and expanded equity capacity improves liquidity but materially increases share count. Reliance on equity-linked financing structurally dilutes existing shareholders and can elevate the long-term cost of capital, affecting per-share economics.

SELLAS Life Sciences Group News

Sellas Life Sciences rises 16.8%

Sellas Life Sciences (SLS) is up 16.8%, or $2.08 to $14.47. Published first on TheFly – the ultimate...

2h ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: KULR Technology Group (KULR)...

3d ago

CGC

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amplitech Group Inc (AMPG)...

12d ago

SLS

AMPG

SELLAS Updates Executive Severance and Change-of-Control Terms

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). On June 24, 2026, SELLAS...

4d ago

SLS

SELLAS Stockholders Approve Governance and Equity Plan Changes

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On June 16, 2026, SELLAS...

11d ago

SLS

SELLAS Life Sciences boosts liquidity through warrant exercises

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). SELLAS Life Sciences Group, Inc....

27d ago

SLS

SELLAS Gains Buy Rating as REGAL Milestones Approach and Pipeline Expands; $10 Price Target Reaffirmed

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SELLAS Life Sciences Group. The associated...

2M ago

SLS

Closing Bell Movers: Karman falls over 10% after Q1 earnings miss

High-flying semiconductors and memory names were some of the worst-hit stocks on Tuesday as investors – fretting over...

2M ago

AIP

INR

Sellas Life Sciences reports Q1 EPS (5c), two estimates (6c)

“The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our...

2M ago

SLS

Sellas Life Sciences options imply 4.6% move in share price post-earnings

Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 16:1. Implied volatility suggests...

2M ago

SLS

Sellas Life Sciences call volume above normal and directionally bullish

Bullish option flow detected in Sellas Life Sciences (SLS) with 7,282 calls trading, 1.8x expected, and implied vol...

2M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: DeFi Development Corp (DFDV)...

3M ago

SLS

DFDV

BUY Rating on SELLAS: Pivotal REGAL Phase 3 Progress, Expanding AML Pipeline, and Cash Runway into 2027 Support Upside Potential

Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group yesterday and set a...

3M ago

SLS

Sellas Life Sciences files automatic mixed securities shelf

17:02 EDT Sellas Life Sciences (SLS) files automatic mixed securities shelf Published first on TheFly – the ultimate...

3M ago

SLS

RXK3 FAQ

What was Sellas Life Sciences Group’s price range in the past 12 months?

Sellas Life Sciences Group lowest stock price was €1.20 and its highest was €7.96 in the past 12 months.

What is Sellas Life Sciences Group’s market cap?

Sellas Life Sciences Group’s market cap is €2.02B.

When is Sellas Life Sciences Group’s upcoming earnings report date?

Sellas Life Sciences Group’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.

How were Sellas Life Sciences Group’s earnings last quarter?

Sellas Life Sciences Group released its earnings results on May 12, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.052 by €0.009.

Is Sellas Life Sciences Group overvalued?

According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sellas Life Sciences Group pay dividends?

Sellas Life Sciences Group does not currently pay dividends.

What is Sellas Life Sciences Group’s EPS estimate?

Sellas Life Sciences Group’s EPS estimate is -0.04.

How many shares outstanding does Sellas Life Sciences Group have?

Sellas Life Sciences Group has 186,032,580 shares outstanding.

What happened to Sellas Life Sciences Group’s price movement after its last earnings report?

Sellas Life Sciences Group reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.052. Following the earnings report the stock price went up 28.767%.

Which hedge fund is a major shareholder of Sellas Life Sciences Group?

Currently, no hedge funds are holding shares in DE:RXK3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SELLAS Life Sciences Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

-47.12%

Trailing 12-Months

Asset Growth

226.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sellas Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group (RXK3) Earnings & Revenues

Historic Earnings Reports

RXK3 Stock 12 Month Forecast

Average Price Target

€8.80

▲(360.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.8024992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8024992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8024992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,7.8586537846153846,7.93730756923077,8.015961353846153,8.094615138461538,8.173268923076924,8.251922707692307,8.330576492307692,8.409230276923077,8.48788406153846,8.566537846153846,8.645191630769231,8.723845415384615,{"y":8.8024992,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,7.8586537846153846,7.93730756923077,8.015961353846153,8.094615138461538,8.173268923076924,8.251922707692307,8.330576492307692,8.409230276923077,8.48788406153846,8.566537846153846,8.645191630769231,8.723845415384615,{"y":8.8024992,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.78,7.8586537846153846,7.93730756923077,8.015961353846153,8.094615138461538,8.173268923076924,8.251922707692307,8.330576492307692,8.409230276923077,8.48788406153846,8.566537846153846,8.645191630769231,8.723845415384615,{"y":8.8024992,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.484,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.802,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.612,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.328,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.652,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.348,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.115,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >